2. 2022 EBMT ABSTRACT OS08-02 PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 1-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 (C6...
In cohort 1, 34 (85.0%) of 40 patients had discontinued the treatment by the cutoff date, and 6 (15.0%) patients remained on treatment (Fig. 1C and Supplementary Fig. 1). Twenty-two (64.7%) of the 34 patients were discontinued because of disease progression, and one (2.9%) patient ...
In our cohort, 57.1% of the patients were under the age of 50, and 42.9% were 50 or older, mirroring the age distribution for HBV-related HCC in China. In summary, the regimen combining camrelizumab, apatinib, and HAIC demonstrated efficacy and safety in treating BCLC stage C HCC ...
On the basis of the average peak concentrations of dabigatran observed in patients with atrial fibrillation who received dabigatran 150 mg twice daily in the RE-LY study (which enrolled a cohort of patients aged ≥65 years with a moderate-to-high comorbidity burden), it was calculated that a ...
Patients were enrolled in cohorts of 3 to 6 patients, with the most recently completed cohort receiving doses of 0.5 mg/kg to 1 mg/kg. Pre-planned analysis of safety and tolerability was conducted at the completion of a 56-day dose-limiting toxicity observation period. RESULTS Between August...
Cohort 1: R/R extranodal NK/T-cell lymphoma (n = 22); cohort 2: R/R mature T-cell neoplasms (n = 44; 21 peripheral T-cell lymphoma not otherwise specified; 11 angioimmunoblastic T-cell lymphoma; 12 anaplastic large cell lymphoma); cohort 3: R/R cutaneous T-cell lymphomas (CTCL;...
No obvious relation between the incidence or titer of positive anti-drug antibody and dosage was observed in each cohort. The biodistribution study indicated that meplazumab reached lung tissue and maintained >14 days stable with the lung tissue/cardiac blood–pool ratio ranging from 0.41 to 0.32...
A Phase 2, single-arm trial was designed to evaluate CV301 plus atezolizumab as first-line treatment for cisplatin-ineligible advanced urothelial carcinoma (aUC) (Cohort 1) or progressing after platinum chemotherapy (Cohort 2). MVA-CV301 was given subcutaneously (SC) on Days 1 and 22 and FPV...
Eight of the 15 patients (53.3%) experienced at least one serious adverse event, resulting in discontinuation of study for 6 (40%) patients. One patient had a bowel perforation. One patient (3 mg/kg cohort) experienced a treatment-related grade 5 cardiopulmonary arrest resulting in death. ...
5i). In a recent large cohort for NSCLC receiving immune checkpoint blockades,27 higher TYROBP expression tendency was also observed in responders (Supplementary Fig. 5j). Meanwhile, patients with higher TYROBP expression also showed better OS (P = 0.0016) and PFS (P = 0.00076) in ...